Aurion Biotech's manufacturing approach to unmodified allogeneic corneal endothelial cells offers a set of hard-won lessons for a cell therapy field still working out how to get from proof-of-concept to broad patient access.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.
The collaboration combines Celonic’s biologics expertise with Carbogen Amcis’s payload and conjugation capabilities to create a seamless, end-to-end ADC development pathway.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.